Nomura has revised its price target for Gland Pharma to ₹3,750, citing a strategic pivot toward becoming a global CDMO partner. The firm's transition into biologics and a 1.7 billion-unit capacity are key drivers for the expected 20% revenue growth. Investors are tracking how effectively the company executes this transition amid valuation and integration challenges.
Nomura has updated its outlook on Gland Pharma, setting a target price of ₹3,750. This revision comes as the company accelerates its transition into a specialized Contract Development and Manufacturing Organization (CDMO). The brokerage expects this strategic pivot, supported by a significant annual injectable capacity of 1.7 billion units, to fuel a 20% revenue compound annual growth rate over the coming years.
The shift toward the CDMO model is designed to move Gland Pharma away from purely generic products toward higher-value partnerships with global innovators. As part of this push, the company is investing heavily in biologics drug substance and product capabilities. Recently, the company also expanded its US footprint, with its board approving a USD 21 million investment to acquire a 60% stake in Novelstar Pharma Inc. earlier in October 2026.
Financially, Gland Pharma reported a consolidated revenue of ₹18,003 million and a net income of ₹3,170 million for the first quarter of the 2027 fiscal year. While these numbers provide a stable foundation, the market's focus remains on whether the company can successfully scale its newer initiatives. The success of this strategy relies heavily on the integration of its European subsidiary, Cenexi. Gland Pharma is currently working to streamline operations at Cenexi sites to improve profit margins, which have previously lagged behind the company's core injectables business.
Investors are keeping a close watch on potential risks that come with this transition. The move into biologics requires different regulatory and technical expertise compared to the company's traditional manufacturing strengths. There is also the risk of capacity underutilization if demand for newer segments, such as GLP-1 cartridges, does not meet internal projections. Additionally, with the stock trading at a forward price-to-earnings (P/E) ratio of approximately 30.6x, the company is priced for growth, meaning consistent execution is required to justify this valuation compared to global CDMO peers.
The next phase for shareholders will depend on the management's ability to secure long-term innovator contracts and deliver on the margin improvement targets for its subsidiary operations. Market participants will likely track upcoming quarterly updates to see if the revenue growth from these new high-value segments begins to outweigh the costs of expansion and integration.